The clinical implementation of CD19-targeting Chimeric Antigen Receptor (CAR)-T cell therapy is promising for patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (r/r) DLBCL [1]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.